CO4700426A1 - SPECIFIC LEAGUES OF NEUROPEPTIDE Y1 - Google Patents

SPECIFIC LEAGUES OF NEUROPEPTIDE Y1

Info

Publication number
CO4700426A1
CO4700426A1 CO96022963A CO96022963A CO4700426A1 CO 4700426 A1 CO4700426 A1 CO 4700426A1 CO 96022963 A CO96022963 A CO 96022963A CO 96022963 A CO96022963 A CO 96022963A CO 4700426 A1 CO4700426 A1 CO 4700426A1
Authority
CO
Colombia
Prior art keywords
neuropeptide
leagues
specific
specific leagues
receptors
Prior art date
Application number
CO96022963A
Other languages
Spanish (es)
Inventor
John M Peterson
Charles A Blum
Goulin Cai
Alan Hutchison
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1995/014472 external-priority patent/WO1996014307A1/en
Application filed by Pfizer filed Critical Pfizer
Publication of CO4700426A1 publication Critical patent/CO4700426A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LOS COMPUESTOS QUE INTERACCIONAN CON RECEPTORES DE NPY1 E INHIBEN LA ACTIVIDAD DEL NEUROPEPTIDO Y EN ESTOS RECEPTORES SON UTILES EN EL TRATAMIENTO DE TRASTORNOS DE LA ALIMENTACION TALES COMO, POR EJEM PLO, OBESIDAD Y BULIMIA Y CIERTAS ENFERMEDADES CARDIOVASCULARES, TALES COMO, POR EJEMPLO HIPERTEN SION.THE COMPOUNDS THAT INTERACT WITH NPY1 RECEPTORS AND INHIBIT THE ACTIVITY OF THE NEUROPEPTIDE AND IN THESE RECEPTORS ARE USEFUL IN THE TREATMENT OF EATING DISORDERS SUCH AS, FOR EXAMPLE, OBESITY AND BULIMIA, AND SOME CARDIOVASCAL DISEASES. .

CO96022963A 1995-06-07 1996-05-08 SPECIFIC LEAGUES OF NEUROPEPTIDE Y1 CO4700426A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47838395A 1995-06-07 1995-06-07
US48497495A 1995-06-07 1995-06-07
PCT/US1995/014472 WO1996014307A1 (en) 1994-11-07 1995-11-07 Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands

Publications (1)

Publication Number Publication Date
CO4700426A1 true CO4700426A1 (en) 1998-12-29

Family

ID=27045885

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96022963A CO4700426A1 (en) 1995-06-07 1996-05-08 SPECIFIC LEAGUES OF NEUROPEPTIDE Y1

Country Status (11)

Country Link
EP (1) EP0833823A1 (en)
JP (1) JPH10507203A (en)
AU (1) AU5578796A (en)
BR (1) BR9609334A (en)
CA (1) CA2220958A1 (en)
CO (1) CO4700426A1 (en)
IL (1) IL117997A0 (en)
MA (1) MA23860A1 (en)
PE (1) PE34297A1 (en)
TR (1) TR199600382A2 (en)
WO (1) WO1996040660A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0915859T3 (en) * 1996-07-23 2003-03-03 Neurogen Corp Certain substituted benzylamine derivatives; a new class of Neuropeptide Y1-specific ligands
WO1998003493A1 (en) * 1996-07-23 1998-01-29 Neurogen Corporation Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands
US6133265A (en) * 1996-07-23 2000-10-17 Neurogen Corporation Certain amido- and amino- substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands
CA2251368A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
AU6267198A (en) * 1997-02-14 1998-09-08 Bayer Corporation Amides as npy5 receptor antagonists
US6048900A (en) * 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
US6420130B1 (en) 1998-12-14 2002-07-16 Aurora Biosciences Corporation Optical molecular sensors for cytochrome P450 activity
DK1140888T3 (en) * 1998-12-14 2003-08-25 Vertex Pharma San Diego Llc Optical molecular sensors for cytochrome P450 activity
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
ZA200508439B (en) 2003-05-05 2007-03-28 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
CA2544573A1 (en) 2003-11-03 2005-06-02 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
AU2005210004B2 (en) 2004-02-05 2010-10-28 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
EP1834953A1 (en) 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
SI2091948T1 (en) 2006-11-30 2012-07-31 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
ES2570167T3 (en) 2011-03-16 2016-05-17 Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845221A (en) * 1988-04-15 1989-07-04 American Home Products Corporation Serotonergic substituted piperazinyl tetralins
ES2130116T3 (en) * 1989-04-22 1999-07-01 Wyeth John & Brother Ltd PIPERAZINE DERIVATIVES.

Also Published As

Publication number Publication date
IL117997A0 (en) 1996-10-31
AU5578796A (en) 1996-12-30
BR9609334A (en) 1999-05-25
WO1996040660A1 (en) 1996-12-19
PE34297A1 (en) 1997-09-24
EP0833823A1 (en) 1998-04-08
MA23860A1 (en) 1996-12-31
MX9709980A (en) 1998-03-29
JPH10507203A (en) 1998-07-14
CA2220958A1 (en) 1996-12-19
TR199600382A2 (en) 1996-12-21

Similar Documents

Publication Publication Date Title
CO4700426A1 (en) SPECIFIC LEAGUES OF NEUROPEPTIDE Y1
UY28442A1 (en) INDAZOL 3.5-DISPOSED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS TO INTERVENE IN OR INHIBIT THE CELL PROLIFERATION
YU47525B (en) GREEN GLASS FOR INFRARED AND ULTRASOUND RADIATION ABSORPTION AND AUTOMOBILE GLASS MADE OF THE SAME
UY26130A1 (en) COMPOUNDS TO TREAT OBESITY
UY26190A1 (en) TIAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEINKINASES AND METHODS FOR THEIR USE
UY26231A1 (en) INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF PROTEIN KINASE AND METHOD FOR USE. UNDER LAW 17,164
GT199900067A (en) NEW 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURTIC DEDERMATOSIS.
ES2097341T3 (en) SUBSTITUTED INDOLES AS DRUGS FOR THE TREATMENT OF AIDS.
SV2004000061A (en) GLUCOCORTICOID RECEIVER MODULATORS REF. 10118 AMAG / BB
ES2153469T3 (en) COMPOUNDS WITH PROPERTIES TO RELEASE THE GROWTH HORMONE.
ES2170141T3 (en) 4-AMINODERIVATES OF MYCOPHENOLIC ACID WITH IMMUNOSUPPRESSING ACTIVITY.
NO986110L (en) IL-8 receptor antagonists
ES2154674T3 (en) DERIVATIVES OF 1,5-BENZODIACEPINS WITH ANTAGONIST OR AGONIST ACTIVITY OF CCK.
GT200400136A (en) 3.5-DISPOSED INDAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS TO INTERVENE IN OR INHIBIT CELLULAR APPROVALIFERATION.
GT199900070A (en) DERIVATIVES OF ISOTIAZOLE, USEFUL AS ANTI-CANCER AGENTS.
EA200100780A1 (en) TWEAK ANTAGONISTS AND TWEAK RECEPTORS AND THEIR USE FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES
MX9302475A (en) POLYPEPTIDE OF NON-NATURAL ORIGIN THAT HAS THE ACTIVITY OF THE RECOMBINANT FACTOR OF STIMULATION OF THE NEU RECEPTOR AND PROCESS FOR THE PRODUCTION OF MY MO.
ES2058306T3 (en) SUBSTITUTED TETRALINS, CHROMANES AND RELATED COMPOUNDS IN THE TREATMENT OF ASTHMA, ARTHRITIS AND RELATED DISEASES.
UA29466C2 (en) Pharmaceutical composition with antitumour activity
DK1032556T3 (en) Pharmaceutically active compounds and methods of use
TR199700956T1 (en) Indazole carboxamides.
MX9205358A (en) COMPOUNDS TO TREAT DISEASES RELATED TO LEUKOTRENE.
ES2170798T3 (en) BENZOPIRANOS AND ITS USE AS THERAPEUTIC AGENTS.
ES2063747T3 (en) NEW BENZOTIOFENOS THAT HAVE ANTI-ALLERGIC ACTIVITY, AS WELL AS NEW BENZOTIOFENOS AND OTHER SELECTED BENZOTIOFENOS THAT HAVE ACTIVITY FOR THE TREATMENT OF ACUTE RESPIRATORY DISCOMFORT SYNDROME.
ES2100689T3 (en) SYNERGIZING ASSOCIATION THAT HAS AN ANTAGONIST EFFECT ON NK1 AND NK2 RECEPTORS.